FDA-cleared profile

AV Vascular

Philips Medical Systems Nederland B.V. · Radiological images; modality varies or is not specified in FDA list · FDA-cleared (510(k))

Authorized purpose: AV Vascular assists trained healthcare professionals with visualization, assessment, and quantification of vascular anatomy on CTA and/or MRA for suspected or diagnosed vascular pathology and pre-procedural endovascular planning.

Clinical role
Segments vessels, creates centerlines and lumen or outer-wall views, provides measurements, and supports review and planning of vascular anatomy.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Vascular anatomy; head/neck, body, aorta, iliac and subclavian vessels
Key limitation
Keep in mind: Use is limited to the supported CTA/MRA anatomy, segmentation, measurements, and pre-procedural workflow; the FDA material warns that accuracy may be reduced for giant aneurysms larger than 10 cm, and clinicians retain final interpretation.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: AV Vascular assists trained healthcare professionals with visualization, assessment, and quantification of vascular anatomy on CTA and/or MRA for suspected or diagnosed vascular pathology and pre-procedural endovascular planning.
  • Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Vascular anatomy; head/neck, body, aorta, iliac and subclavian vessels Input: Supported CTA and/or MRA medical-image datasets, including vascular studies selected for segmentation and planning.
  • Who uses it?Intended users: Radiologists, vascular specialists, interventional radiologists, surgeons, and other trained healthcare professionals reviewing vascular CTA or MRA.
  • What does the software produce?Output: 2D, MIP, MPR, cMPR, sMPR, path-aligned, and 3D displays; vessel centerlines; lumen and outer-wall segmentations; diameters, areas, lengths, angles, ring markers, reports, and exports.
  • What is its most important limitation?Key limitation: Use is limited to the supported CTA/MRA anatomy, segmentation, measurements, and pre-procedural workflow; the FDA material warns that accuracy may be reduced for giant aneurysms larger than 10 cm, and clinicians retain final interpretation.

Clinical takeaway. Clinical role: AV Vascular assists trained healthcare professionals with visualization, assessment, and quantification of vascular anatomy on CTA and/or MRA for suspected or diagnosed vascular pathology and pre-procedural endovascular planning.

Evidence takeaway. Evidence from the reviewed source record: K253735 FDA material reports outer-wall segmentation validation in 80 patients from seven U.S., three European, and one Asian site, with 3D and 2D Dice, mean-surface-distance, Hausdorff-distance, and diameter-error endpoints; the evidence is exact-version and task-specific.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
AV Vascular assists trained healthcare professionals with visualization, assessment, and quantification of vascular anatomy on CTA and/or MRA for suspected or diagnosed vascular pathology and pre-procedural endovascular planning.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Segments vessels, creates centerlines and lumen or outer-wall views, provides measurements, and supports review and planning of vascular anatomy.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported CTA and/or MRA medical-image datasets, including vascular studies selected for segmentation and planning.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
2D, MIP, MPR, cMPR, sMPR, path-aligned, and 3D displays; vessel centerlines; lumen and outer-wall segmentations; diameters, areas, lengths, angles, ring markers, reports, and exports.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Hospital and clinical vascular imaging, radiology, and pre-procedural planning workflows.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Radiologists, vascular specialists, interventional radiologists, surgeons, and other trained healthcare professionals reviewing vascular CTA or MRA.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Use is limited to the supported CTA/MRA anatomy, segmentation, measurements, and pre-procedural workflow; the FDA material warns that accuracy may be reduced for giant aneurysms larger than 10 cm, and clinicians retain final interpretation.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
K253735 FDA material reports outer-wall segmentation validation in 80 patients from seven U.S., three European, and one Asian site, with 3D and 2D Dice, mean-surface-distance, Hausdorff-distance, and diameter-error endpoints; the evidence is exact-version and task-specific.
  • Exact FDA submission
  • Checked 2026-09-04

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K253735 FDA material reports outer-wall segmentation validation in 80 patients from seven U.S., three European, and one Asian site, with 3D and 2D Dice, mean-surface-distance, Hausdorff-distance, and diameter-error endpoints; the evidence is exact-version and task-specific.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, and source if later verified.

Outer-wall segmentation 3D Dice

0.96 Dice coefficient

  • Endpoint3D aorto-iliac outer-wall segmentation agreement
  • Population80-patient multi-site validation cohort
  • Tested versionAV Vascular configuration described in K253735

Outer-wall segmentation 2D Dice

0.96 Dice coefficient

  • Endpoint2D aorto-iliac outer-wall segmentation agreement
  • Population80-patient multi-site validation cohort
  • Tested versionAV Vascular configuration described in K253735

Outer-wall mean surface distance

0.57 mm

  • EndpointMean surface distance for outer-wall segmentation
  • Population80-patient multi-site validation cohort
  • Tested versionAV Vascular configuration described in K253735

Outer-wall Hausdorff distance

1.68 mm

  • EndpointHausdorff distance for outer-wall segmentation
  • Population80-patient multi-site validation cohort
  • Tested versionAV Vascular configuration described in K253735

Minimum-diameter error within 5 mm

98.8 percent

  • EndpointProportion of diameter errors within 5 mm for minimum diameter
  • Population80-patient multi-site validation cohort
  • Tested versionAV Vascular configuration described in K253735

Maximum-diameter error within 5 mm

98.5 percent

  • EndpointProportion of diameter errors within 5 mm for maximum diameter
  • Population80-patient multi-site validation cohort
  • Tested versionAV Vascular configuration described in K253735

K253735 FDA evidence package for AV Vascular

  • DesignFDA 510(k) retrospective multi-site vascular segmentation and measurement validation.
  • Population80 patients with aorto-iliac vascular studies from seven U.S., three European, and one Asian site, independent from training sites.
  • Scopeexact submission
  • Tested versionAV Vascular configuration described in K253735
  • Samplen=80
  • Sites11
  • IndependenceSponsor or vendor study

K253735

The FDA material also describes centerline, ring-marker, and subclavian tests; no broader clinical-outcome claim is promoted.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K253735 by exact native submission identifier. This does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging or clinical service line and verify payer, site-of-service, coding, and coverage assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-04

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This is not a product-specific reimbursement determination. Verify payer, site-of-service, coding, and coverage assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported CTA and/or MRA medical-image datasets, including vascular studies selected for segmentation and planning.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K253735: AV Vascular

  2. Routing

    Source context, not route validation: The FDA material describes CTA/MRA input, multiple 2D and 3D visualization paths, segmentation, centerline and measurement outputs, reports, exports, and ring-marker planning functions.

    Scope: Exact FDA submission. This is the interface boundary described in the exact FDA decision material; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K253735: AV Vascular

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: 2D, MIP, MPR, cMPR, sMPR, path-aligned, and 3D displays; vessel centerlines; lumen and outer-wall segmentations; diameters, areas, lengths, angles, ring markers, reports, and exports.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K253735: AV Vascular

  5. Viewer/worklist/report

    Unresolved route: 2D, MIP, MPR, cMPR, sMPR, path-aligned, and 3D displays; vessel centerlines; lumen and outer-wall segmentations; diameters, areas, lengths, angles, ring markers, reports, and exports.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K253735: AV Vascular

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
The FDA material describes CTA/MRA input, multiple 2D and 3D visualization paths, segmentation, centerline and measurement outputs, reports, exports, and ring-marker planning functions.
  • Exact FDA submission
  • Checked 2026-09-04

This is the interface boundary described in the exact FDA decision material; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.

Security
Philips' Responsible Disclosure Statement states that Philips maintains a global network of product security officers for developing and deploying security and privacy features for its products and services and for managing security events; that vulnerability reports to productsecurity@philips.com (PGP-encrypted) are acknowledged within two business days with a tracking number and an assigned contact; status updates approximately every 2-3 weeks; a 90-day resolution aim; and patch or advisory notification through existing customer notification processes. Vendor statement; no certification or test report was read.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: the statement is on philips.com (Royal Philips) and covers Philips products and services; the FDA applicant entity appears in Philips' own BCR members list on documents.philips.com (Philips Ultrasound LLC, Philips Medical Systems Nederland B.V., Philips Healthcare (Suzhou), Philips Medical Systems DMC GmbH, Philips Medical Systems Technologies Ltd., Philips Oy). Corporate policy; exact-release scope is not established.

Training
Only Radiologists, vascular specialists, interventional radiologists, surgeons, and other trained healthcare professionals reviewing vascular CTA or MRA should operate or interpret the product; local onboarding must cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor K253735 by exact hardware, software, model, algorithm version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track these product-specific limits: Use is limited to the supported CTA/MRA anatomy, segmentation, measurements, and pre-procedural workflow; the FDA material warns that accuracy may be reduced for giant aneurysms larger than 10 cm, and clinicians retain final interpretation.
  • Exact FDA submission
  • Checked 2026-09-04

Buyer-facing monitoring guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.

Release and scope verification

Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K253735 before acceptance.

exact submission · checked 2026-09-04

Later product-family features are not evidence that this cleared release includes them.

Deployment boundary

The exact public deployment topology remains incomplete; establish hosting responsibility, data flow, availability, upgrade, service, and downtime boundaries locally.

exact submission · checked 2026-09-04

FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.

Interoperability acceptance

The FDA material describes CTA/MRA input, multiple 2D and 3D visualization paths, segmentation, centerline and measurement outputs, reports, exports, and ring-marker planning functions.

exact submission · checked 2026-09-04

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Use is limited to the supported CTA/MRA anatomy, segmentation, measurements, and pre-procedural workflow; the FDA material warns that accuracy may be reduced for giant aneurysms larger than 10 cm, and clinicians retain final interpretation.

exact submission · checked 2026-09-04

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-04

No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.

Lifecycle monitoring

Monitor K253735 by exact hardware, software, model, algorithm version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates.

exact submission · checked 2026-09-04

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K253735
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiological images; modality varies or is not specified in FDA list
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Vascular anatomy; head/neck, body, aorta, iliac and subclavian vessels
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-01-22
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
32Fields reviewed
10Source classes checked
16Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads

Screened 16 PubMed and one ClinicalTrials.gov record. Their AV or vascular wording concerns arteriovenous access, thrombosis, or unrelated biology rather than Philips AV Vascular or K253735; all 17 were quarantined and none was promoted. The current discovery snapshot contains 16 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    The exact public FDA decision material does not establish the complete deployment topology, hosting responsibility, availability, upgrade path, or service contract.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

8 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K253735: AV Vascular

    U.S. Food and Drug Administration - Published 2026-01-22 - Accessed 2026-09-04

    Scope: identity, productIdentity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. AV Vascular model card (K253735)

    American College of Radiology - Published 2026-09-01 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, evidenceSummary, anatomy, evidenceStudies

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  8. Philips: Responsible Disclosure Statement

    Philips - Accessed 2026-10-26

    Scope: security

Research history

  1. K253735 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K253969

ADAS 3D

Adas3D Medical S.L.

Authorized purpose: ADAS 3D supports visualization and analysis of MR and CT images of the heart for individual patients with cardiovascular disease, including patients with myocardial scar from ischemic or non-ischemic heart disease. Qualified professionals may use it for cardiac calculation, quantification, visualization, pre-planning, and electrophysiology procedures; produced data support clinical decision-making and must not be used as irrefutable medical advice or for radiotherapy planning, dose calculation, or treatment delivery.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Heart; myocardial scar and cardiac structures
Decision
2026-06-29
FDA-cleared K260316

CMN Capillary Function with Oncology Virtual Expert

Cercare Medical A/S

Authorized purpose: Cercare Neurosuite with Capillary Function and Oncology Virtual Expert processes CT or MR information to provide perfusion, tissue-blood-volume, diffusion, labeling, and quantification support for adult brain glioma workflows.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain
Decision
2026-06-22
FDA-cleared K261713

Synapse PACS (7.6.0)

FUJIFILM Healthcare Americas Corporation

Synapse PACS 7.6.0 provides medical-image management and processing, including measurements, regional segmentation, clinical calculations, structured reports, comparison, fusion, and volume rendering to aid reading, interpretation, reporting, and treatment planning.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
N/A
Decision
2026-06-18
FDA-cleared K252563

Neurophet SCALE PET

Neurophet., Inc.

Authorized purpose: Brain MRI/PET registration, segmentation and quantitative PET assessment

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain
Decision
2026-05-15

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history